These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11586005)

  • 1. Optimal treatment strategies for acute exacerbations of chronic bronchitis: high-risk patients.
    Norrby SR
    Chemotherapy; 2001; 47 Suppl 4():47-52; discussion 53-4. PubMed ID: 11586005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotics in the treatment of acute exacerbations of chronic bronchitis.
    Dever LL; Shashikumar K; Johanson WG
    Expert Opin Investig Drugs; 2002 Jul; 11(7):911-25. PubMed ID: 12084002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis.
    Masterton RG; Burley CJ
    Int J Antimicrob Agents; 2001 Dec; 18(6):503-12. PubMed ID: 11738336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort.
    Urueta-Robledo J; Ariza H; Jardim JR; Caballero A; García-Calderón A; Amábile-Cuevas CF; Hernández-Oliva G; Vivar-Orozco R;
    Respir Med; 2006 Sep; 100(9):1504-11. PubMed ID: 16504492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
    Langtry HD; Lamb HM
    Drugs; 1998 Sep; 56(3):487-515. PubMed ID: 9777318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ; Jung R; Garvin CG
    Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Levofloxacin in the treatment of respiratory infections].
    Iakovlev SV; Iakovlev VP
    Antibiot Khimioter; 2002; 47(8):32-42. PubMed ID: 12515095
    [No Abstract]   [Full Text] [Related]  

  • 8. Levofloxacin: an updated review of its use in the treatment of bacterial infections.
    Hurst M; Lamb HM; Scott LJ; Figgitt DP
    Drugs; 2002; 62(14):2127-67. PubMed ID: 12269858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights in the treatment by levofloxacin.
    File TM
    Chemotherapy; 2004; 50 Suppl 1():22-8. PubMed ID: 15319551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
    Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
    Cantón R; Lode H; Graninger W; Milkovich G
    Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S115-27. PubMed ID: 16904873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis.
    Blasi F; Schaberg T; Centanni S; Del Vecchio A; Rosignoli MT; Dionisio P
    Pulm Pharmacol Ther; 2013 Oct; 26(5):609-16. PubMed ID: 23538168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis.
    Cazzola M; Salvatori E; Dionisio P; Allegra L
    Pulm Pharmacol Ther; 2006; 19 Suppl 1():30-7. PubMed ID: 16359895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis.
    Nicolau DP; Sutherland C; Winget D; Baughman RP
    Pulm Pharmacol Ther; 2012 Feb; 25(1):94-8. PubMed ID: 22210007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Update on the use of levofloxacin in the management of acute exacerbations of chronic bronchitis with risk factors].
    Zuck P
    Presse Med; 2002 Jun; 31(21 Pt 2):S15-8. PubMed ID: 12148385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)].
    Scheen AJ
    Rev Med Liege; 2000 Nov; 55(11):1015-7. PubMed ID: 11195704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials.
    Dimopoulos G; Siempos II; Korbila IP; Manta KG; Falagas ME
    Chest; 2007 Aug; 132(2):447-55. PubMed ID: 17573508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levofloxacin: a therapeutic review.
    Wimer SM; Schoonover L; Garrison MW
    Clin Ther; 1998; 20(6):1049-70. PubMed ID: 9916602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levofloxacin, a second-generation fluoroquinolone.
    North DS; Fish DN; Redington JJ
    Pharmacotherapy; 1998; 18(5):915-35. PubMed ID: 9758306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis.
    Amsden GW; Baird IM; Simon S; Treadway G
    Chest; 2003 Mar; 123(3):772-7. PubMed ID: 12628877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.